Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OYUQB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DB-2304
|
|||||
| Synonyms |
DB-2304
Click to Show/Hide
|
|||||
| Organization |
Duality Biotherapeutics (DualityBio) (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Hu033-03
|
Antibody Info | ||||
| Antigen Name |
C-type lectin domain family 4 member C (CLEC4C)
|
Antigen Info | ||||
| Payload Name |
P2025
|
Payload Info | ||||
| Therapeutic Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Lupus erythematosus |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion for Part A: healthy volunteers aged 18-55; BMI-compliant; normal medical history/physical exams/lab tests/ECG; commitment to effective contraception and protocol compliance.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06625671 | Clinical Status | PHASE1 | ||
| Clinical Description | A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DB-2304 Injection in Healthy Adult Participants | ||||
| Primary Endpoint |
Primary safety endpoints include TEAEs and SAEs (monitored up to 112 days for Part A/196 days for Part B post-treatment), ECG parameters (HR/PR/QT/QTcF intervals), and vital sign measurements (weight, heart rate, pulse, respiratory rate, body temperature) with baseline change analysis.
|
||||